Takeda entered into an exclusive licensing agreement with Hutchmed Limited to develop its colorectal cancer candidate, fruquintinib, beyond mainland China, Hong Kong and Macau.
Featured Posts
Sanofi licensed CytoReason’s inflammatory bowel disease model in a multi-million dollar bid to identify new therapies for IBD and Crohn’s and colitis.
The U.S. health regulator proposed the use of one dose of the latest updated COVID-19 shot annually for healthy adults, similar to the influenza immunization campaign, as it aims to simplify the country’s current COVID-vaccine strategy.
With the approval, Tukysa became the first FDA-approved treatment for RAS wild-type, HER2-positive metastatic colon cancer, a cancer with historically poor outcomes.
The subvariant is estimated to have accounted for 49.1% of COVID cases in the country in the week ended Jan. 21, compared with 37.2% estimated last week.
U.S. government plans to rein in drug prices could discourage work in some of Novartis’s most promising areas of research, the Swiss drugmaker warned, urging Washington to rethink the “unintended” effects of its new rules.
Disc Medicine inked an exclusive license agreement with Mabwell Therapeutics for the latter’s portfolio of monoclonal antibodies against the TMPRSS6 protein.
The FDA issued a complete response letter refusing accelerated approval for Eli Lilly’s Alzheimer’s disease candidate donanemab, the Indianapolis-based company announced yesterday.
Sinopharm, now the China distributor of Merck & Co’s COVID-19 antiviral treatment molnupiravir, said its biotech unit received clinical trial approval from the National Medical Products Administration.
According to data from the IMbrave150 study, the drug combo is the first treatment option in over a decade to confer significant overall survival benefit over standard of care in unresectable hepatocellular carcinoma.